Collagen Peptides in Focus: Research Gaps, Proven Benefits, and Formulation Strategy

United Kingdom — 19 July 2026

Despite the ubiquitous marketing claims, are all collagen peptides truly created equal when it comes to bioavailability? While bovine and marine sources dominate the market, often lauded for their purported superior absorption, the science behind these distinctions, particularly compared to emerging plant-derived alternatives, remains nuanced. Formulators must look beyond the marketing gloss to the hard data to discern where real value lies, rather than simply chasing the latest trend.

What the Clinical Evidence Actually Shows

Clinical studies on collagen peptides primarily focus on hydrolysed forms, typically Type I or Type II, derived from bovine or marine sources. Trials often utilise daily doses ranging from 2.5g to 10g. For instance, a 2015 study published in the Journal of Medical Nutrition and Nutraceuticals showed a 13% improvement in skin elasticity after 8 weeks with 5g/day of hydrolysed marine collagen, yet similar benefits have been observed with bovine sources. The critical factor appears to be the hydrolysis process, which reduces collagen into smaller, absorbable peptides. Dr. Eleanor Vance, a senior research fellow in nutraceuticals at the University of Reading, notes,

"The digestive system breaks down collagen into amino acids and di- and tripeptides regardless of its original animal source. The real bioavailability question hinges on the efficiency of peptide absorption, not the species of origin."

Plant-derived collagens, often synthesised through fermentation or extracted from plant proteins, present a different challenge. While they offer an ethical alternative, robust human clinical trials demonstrating comparable efficacy and bioavailability to animal-derived hydrolysates are still emerging. Many 'plant collagens' are, in fact, blends of amino acids, vitamins, and minerals that support endogenous collagen synthesis, rather than true collagen peptides themselves. Formulators must scrutinise the evidence base for each specific ingredient, rather than relying on category-wide assumptions.

The Formulation Reality

The practicalities of formulating with collagen peptides extend beyond raw material sourcing. Bioavailability is significantly influenced by peptide size distribution, which is a direct result of the hydrolysis method. Smaller peptides (e.g., <2 kDa) are generally considered more bioavailable. Excipient interactions, particularly with high-pH ingredients or those containing proteolytic enzymes, can degrade peptide integrity, compromising efficacy and shelf stability. Formulators must consider the finished product matrix; liquid formulations may experience different stability profiles than powders or capsules. For instance, maintaining a pH range of 4-7 is often crucial for peptide stability. "The matrix effect is frequently underestimated," states Mr. David Chen, Head of R&D at NutraForm Solutions.

"A poorly formulated liquid collagen, even with premium raw materials, can deliver fewer bioavailable peptides than a well-engineered powder."

Moisture content and packaging are also critical to prevent aggregation and maintain solubility over the product's shelf life, directly impacting consumer experience and perceived efficacy.

Market Position and Commercial Viability

The global collagen market was valued at approximately £3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 6.5% through to 2030. This growth is largely driven by the beauty-from-within and healthy ageing segments. Bovine collagen typically offers a lower raw material cost and greater supply chain stability compared to marine collagen, which can be subject to seasonal fishing quotas and higher processing costs. Plant-derived options, while commanding a premium due to novelty and ethical positioning, often have higher MOQs and longer lead times from specialised manufacturers. For manufacturers, gross margins on finished collagen products can range from 30% to 55%, heavily dependent on batch size, formulation complexity, and brand positioning. Pricing pressures are increasing as the market matures, necessitating efficient sourcing and manufacturing processes to maintain profitability. Brands must decide whether the premium associated with marine or plant-derived collagen justifies the increased input costs and potential market resistance, especially when the bioavailability advantage is not definitively proven.

What This Means for United Kingdom

The UK consumer market for collagen peptides is robust, mirroring global trends towards health and wellness. However, regulatory scrutiny, particularly from the Food Standards Agency (FSA) and Advertising Standards Authority (ASA), demands rigorous substantiation for any health claims. Generic 'collagen' claims are permissible, but specific health benefits require adherence to authorised EU/UK health claims regulations, which are limited in this category. The competitive landscape is saturated, with both established pharmaceutical brands and agile D2C companies vying for market share. Consumer demand for ethical sourcing and sustainability is growing, creating an opening for well-evidenced plant-derived alternatives, provided they can overcome the bioavailability hurdle. Brands must navigate this environment with transparent sourcing, clear messaging, and a focus on demonstrable product quality to differentiate themselves.

The Bottom Line for Formulators

Formulators should invest in collagen peptides, but with a critical eye. Prioritise hydrolysed forms with robust data on peptide size distribution. While marine and bovine sources remain the gold standard for clinical efficacy, the choice between them should be driven by cost, sustainability goals, and target consumer. Plant-derived options offer market differentiation but require significantly more R&D investment to validate true collagen peptide efficacy and bioavailability. Do not assume all collagens are metabolically equivalent; scrutinise the science for each specific ingredient and ensure your formulation protects peptide integrity. The commercial success lies in quality, substantiated claims, and strategic positioning, not simply ingredient origin.